

Navitoclax

Catalog No: tcsc0013

Available Sizes

Size: 10mg

Size: 5mg

Size: 25mg

Size: 50mg

Size: 100mg



Specifications

CAS No: 923564-51-6

Formula:

C₄₇H₅₅CIF₃N₅O₆S₃

Pathway: Apoptosis

Target: Bcl-2 Family

Purity / Grade:

>98%

Solubility:

DMSO : 75 mg/mL (76.95 mM; Need ultrasonic); H2O :

Alternative Names:

ABT-263

Copyright 2021 Taiclone Biotech Corp.



Observed Molecular Weight:

974.61


Product Description

Navitoclax (ABT-263) is a potent and oral **Bcl-2 family protein** inhibitor that binds to multiple anti-apoptotic Bcl-2 family proteins, such as $Bcl-x_{L}$, Bcl-2 and Bcl-w, with a K_{i} of less than 1 nM.

IC50 & Target: Ki: L),

In Vitro: Navitoclax (ABT-263) is active against approximately one-half of the cell lines of the PPTP in vitro panel. The median IC_{50} for all of the lines in the panel is 1.91 μ M^[1]. Navitoclax in combination with chemotherapy agents leads most ovarian cancer cell lines a synergistic response, and enhances the caspase activation at all paclitaxel doses tested in both SK-OV-3 and IGROV-1 cell lines^[2].

In Vivo: Navitoclax (100 mg/kg/day, p.o.) also improves responses to bendamustine-rituximab (BR) in a subset of tumours in mice xenograft^[3].



All products are for RESEARCH USE ONLY. Not for diagnostic & therapeutic purposes!

Copyright 2021 Taiclone Biotech Corp.